The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non-Proliferative Diabetic Retinopathy (NPDR). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non-Proliferative Diabetic Retinopathy (NPDR) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Non-Proliferative Diabetic Retinopathy (NPDR) by 14 companies/universities/institutes. The top development phase for Non-Proliferative Diabetic Retinopathy (NPDR) is phase ii with seven drugs in that stage. The Non-Proliferative Diabetic Retinopathy (NPDR) pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline products market are: Kato Pharmaceuticals, EyePoint Pharmaceuticals and Kubota Vision.
The key targets in the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline products market include Vascular Endothelial Growth Factor (VEGF) , Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), and Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1).
The key mechanisms of action in the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline product include Vascular Endothelial Growth Factor (VEGF) Inhibitor with two drugs in Phase II. The Non-Proliferative Diabetic Retinopathy (NPDR) pipeline products include seven routes of administration with the top ROA being Intravitreal and three key molecule types in the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline products market including Small Molecule, and Fusion Protein.
Non-Proliferative Diabetic Retinopathy (NPDR) overview
Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula.
For a complete picture of Non-Proliferative Diabetic Retinopathy (NPDR)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
